A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of CPI-300 Via Intravenous Infusion in Patients With Advanced Solid Tumors
Latest Information Update: 12 Feb 2024
At a glance
- Drugs CPI-300-Coordination Pharmaceuticals (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Coordination Pharmaceuticals
- 05 Feb 2024 Status changed from recruiting to completed.
- 09 Feb 2023 Planned End Date changed from 15 Dec 2022 to 15 Dec 2023.
- 09 Feb 2023 Planned primary completion date changed from 15 Dec 2022 to 15 Dec 2023.